5 completed, 1 active not recruiting, 1 recruiting. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Bumetanide: new trials by email Literature Review of Bumetanide trials Research Report on Bumetanide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects NPT 2042 (bumetanide analog) or Matching Placebo - Epilepsy, Alzheimer Disease | Phase 1 | Completed | NeuroPro Therapeutics, Inc. | 50 | 2022-10-20 | 2023-04-04 |
| Mechanisms of Diuretic Resistance in Heart Failure, Aim 1 Bumetanide Injection - Heart Failure | Phase 1 | Recruiting | Yale University | 75 | 2022-06-01 | 2026-05-22 |
| Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells Hepatic artery embolization (HAE), Bumetanide - Unresectable Hepatocellular Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2017-04-05 | 2026-05-05 |
| Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide), IV Chlorothiazide - Heart Failure | Phase 1 | Completed | Yale University | 458 | 2015-08-31 | 2025-08-17 |
| NEMO1:NEonatal Seizure Using Medication Off-patent Bumetanide - Neonatal Seizures | Phase 1 / Phase 2 | Completed | Great Ormond Street Hospital for Children NHS Foundation Trust | 14 | 2011-08-01 | 2015-09-14 |
| Pilot Study of Bumetanide for Newborn Seizures Bumetanide, Normal Saline as Placebo - Seizures | Phase 1 | Completed | Soul, Janet , M.D. | 43 | 2010-01-01 | 2020-12-17 |
| Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects Bumetanide, Dapagliflozin - Type 2 Diabetes Mellitus | Phase 1 | Completed | AstraZeneca | 42 | 2009-07-01 | 2016-10-17 |
Heart Failure (2) · Hypoxia-Ischemia, Brain (2) · Alzheimer Disease (1) · Central Nervous System Diseases (1) · Diabetes Mellitus, Type 2 (1) · Drug Resistant Epilepsy (1) · Epilepsy (1) · Intracranial Hemorrhages (1) · Seizures (1)
Yale University (2) · AstraZeneca (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · Memorial Sloan Kettering Cancer Center (1) · NeuroPro Therapeutics, Inc. (1) · Soul, Janet , M.D. (1)
United States (6) · Ireland (1) · Netherlands (1) · Sweden (1) · United Kingdom (1)
Hooman Yarmohammadi, MD (1) · Janet Soul, MD,CM (1) · Jeffrey Testani (1) · Jeffrey Testani, MD (1) · Ronit Pressler, Dr (1)
PMID 25765333, PMID 29440005, PMID 36896716, PMID 40938670
R01DK130997 (1), R01HL128973 (1), R01NS066929 (1)